Elekta AB (EKTA.B) AI Stock Analysis

• Market Cap: kr18.29B
• Dividend Yield: 5.01%
• Average Volume (3M): 1.48M
• Price to Earnings (P/E): 66.8
• Beta (1Y): 0.99
• Revenue Growth: -1.54%
• EPS Growth: -75.84%
• Country: SE
• Employees: 4,541
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.31
• Shares Outstanding: 368,587,650
• 10 Day Avg. Volume: 1,505,243
• 30 Day Avg. Volume: 1,477,990
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr47.67
• Price Target Upside: -0.44% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 6

• Rating: 53 Neutral
• Price Target: kr50.00 ▲(4.43% Upside)

Elekta AB's overall stock score is primarily impacted by its financial performance, which shows declining revenue and profitability margins. The technical analysis suggests a neutral to slightly bearish trend, while the high P/E ratio indicates overvaluation despite an attractive dividend yield. The absence of earnings call data and notable corporate events means these factors do not influence the score.

Elekta AB Business Overview & Revenue Model

Company Description

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

How the Company Makes Money

Elekta makes money through a diversified revenue model that includes the sale of medical devices, software solutions, and ongoing service contracts. Key revenue streams are generated from the sale of radiation therapy equipment, such as linear accelerators and brachytherapy systems, as well as treatment planning and imaging software. Additionally, the company earns significant income from maintenance and service agreements, which provide ongoing support and upgrades for their installed equipment. Elekta also benefits from partnerships with healthcare providers and research institutions, which can lead to collaborative projects and additional sales opportunities. Factors contributing to its earnings include a growing demand for cancer treatment solutions, advancements in medical technology, and the expansion of healthcare infrastructure globally.

Elekta AB Financial Statement Overview

Summary

Elekta AB's financial performance is stable but challenged. The company maintains a strong equity base and efficient cash conversion, yet faces profitability and leverage challenges. Revenue and profit margins have been inconsistent, highlighting the need for improved operational efficiency and risk management.

Income Statement

Elekta AB's income statement shows a mixed performance. The company has experienced fluctuations in revenue over the years, with a decline in 2025 compared to 2024. The gross profit margin is relatively stable, but net profit margins have decreased significantly in 2025 due to a lower net income. EBIT and EBITDA margins have also shown a downward trend, indicating reduced operational efficiency.

Balance Sheet

The balance sheet reveals a stable financial position. Elekta AB maintains a healthy equity ratio, suggesting a strong equity base relative to its total assets. However, the debt-to-equity ratio is relatively high, indicating potential leverage risk. Return on equity has declined, reflecting reduced profitability in relation to shareholder equity.

Cash Flow

Cash flow analysis indicates some concerns. Operating cash flow has increased over the years, but the free cash flow growth rate is inconsistent. The operating cash flow to net income ratio is relatively strong, suggesting efficient earnings conversion to cash. However, free cash flow to net income ratio indicates some challenges in maintaining positive free cash flow relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	18.02B	18.02B	18.12B	16.87B	14.55B	13.76B
Gross Profit	6.75B	6.75B	6.80B	6.35B	5.44B	5.61B
EBITDA	1.99B	2.19B	3.29B	2.57B	2.69B	3.07B
Net Income	237.00M	237.00M	1.30B	943.00M	1.15B	1.25B
Balance Sheet
Total Assets	28.98B	28.98B	31.41B	29.61B	26.30B	24.84B
Cash, Cash Equivalents and Short-Term Investments	2.96B	2.96B	2.78B	3.27B	3.07B	4.40B
Total Debt	7.57B	7.57B	7.25B	6.67B	5.70B	6.24B
Total Liabilities	20.13B	20.13B	20.63B	19.88B	17.39B	16.65B
Stockholders Equity	8.80B	8.80B	10.78B	9.73B	8.91B	8.20B
Cash Flow
Free Cash Flow	1.06B	1.06B	817.00M	400.00M	450.00M	1.71B
Operating Cash Flow	2.63B	2.63B	2.46B	1.96B	1.86B	2.55B
Investing Cash Flow	-1.67B	-1.67B	-1.92B	-1.61B	-1.65B	-613.00M
Financing Cash Flow	-606.00M	-607.00M	-1.10B	-129.00M	-1.73B	-3.60B

Elekta AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 47.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Neutral. The current price of 47.88 is below the 20-day moving average (MA) of 48.54, above the 50-day MA of 47.23, and below the 200-day MA of 51.64, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 49.65 is Neutral, neither overbought nor oversold. The STOCH value of 19.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:EKTA.B.

Elekta AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMX	67 Neutral	$41.06B	56.21	20.47%	―	42.25%	210.72%
MCAP	66 Neutral	kr8.68B	43.33	15.85%	―	9.32%	-7.55%
CRAD.B	62 Neutral	kr1.09B	42.21	7.87%	―	-10.34%	-59.69%
VITR	57 Neutral	kr18.57B	40.80	3.46%	0.80%	0.14%	―
RAY.B	54 Neutral	kr8.23B	42.64	22.80%	1.25%	10.98%	27.60%
EKTA.B	53 Neutral	kr18.29B	66.77	2.76%	5.01%	-1.54%	-75.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Elekta AB Corporate Events

Elekta Announces Executive Management Changes to Strengthen Leadership

Elekta has announced significant changes in its executive management, appointing Klara Eiritz as the new Chief Financial Officer, effective by March 2026, while the current CFO, Chief Commercial Officer, and Chief People Officer will leave the company. These changes are part of a strategic restructuring to enhance leadership capabilities and streamline operations, with the goal of improving commercial execution, responding more effectively to customer needs, and delivering sustainable shareholder value.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK34.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta AB’s 2025 AGM Highlights Strategic Initiatives and Shareholder Returns

Elekta AB held its Annual General Meeting on September 4, 2025, where several key resolutions were passed. The meeting approved a dividend payment, re-elected board members, and authorized share acquisitions and transfers. Additionally, a long-term performance-based share program for 2025 was adopted, focusing on shareholder return, hypofractionation installations, and CO2 reduction, indicating Elekta’s commitment to strategic growth and sustainability.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK34.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta AB Reports Strong European Sales and Improved Cash Flow in Q1 2025/26

Elekta AB reported a 3% increase in net sales at constant exchange rates for the first quarter of 2025/26, driven by strong performance in Europe. Despite challenges such as FX effects and tariffs impacting margins, the company improved its cash flow significantly by SEK 529 million due to better working capital management. The company achieved several commercial milestones, including FDA clearance for its Leksell Gamma Knife and a significant deal with the University of Texas Southwestern. Elekta expects continued growth in net sales over the fiscal year, despite anticipated challenges in the US and China markets.

The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK53.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.